These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 15190026

  • 1. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
    Hammerschlag MR, Roblin PM.
    J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
    [No Abstract] [Full Text] [Related]

  • 2. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
    Roblin PM, Hammerschlag MR.
    Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.
    Miyashita N, Fukano H, Yoshida K, Niki Y, Matsushima T.
    J Antimicrob Chemother; 2003 Sep; 52(3):497-9. PubMed ID: 12917246
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM, Reznik T, Kutlin A, Hammerschlag MR.
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of trovafloxacin against Chlamydia pneumoniae.
    Roblin PM, Kutlin A, Hammerschlag MR.
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410
    [Abstract] [Full Text] [Related]

  • 6. In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.
    Smith RP, Baltch AL, Ritz WJ, Carpenter AN, Halse TA, Bopp LH.
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2081-4. PubMed ID: 15155203
    [Abstract] [Full Text] [Related]

  • 7. In vitro activities of five quinolones against Chlamydia pneumoniae.
    Hammerschlag MR, Hyman CL, Roblin PM.
    Antimicrob Agents Chemother; 1992 Mar; 36(3):682-3. PubMed ID: 1320366
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
    Roblin PM, Montalban G, Hammerschlag MR.
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1402-3. PubMed ID: 8092845
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
    Kohlhoff SA, Roblin PM, Reznik T, Hawser S, Islam K, Hammerschlag MR.
    Antimicrob Agents Chemother; 2004 May; 48(5):1885-6. PubMed ID: 15105151
    [Abstract] [Full Text] [Related]

  • 10. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
    Kuo CC, Jackson LA, Lee A, Grayston JT.
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2669-70. PubMed ID: 8913488
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
    Azadian BS, Talboys CA, Roberts AP.
    J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
    [No Abstract] [Full Text] [Related]

  • 12. Potential for antimicrobial resistance in Chlamydia pneumoniae.
    Stamm WE.
    J Infect Dis; 2000 Jun; 181 Suppl 3():S456-9. PubMed ID: 10839739
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.
    Kutlin A, Roblin PM, Hammerschlag MR.
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2268-72. PubMed ID: 10471577
    [Abstract] [Full Text] [Related]

  • 14. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
    Donati M, Rodrìguez Fermepin M, Olmo A, D'Apote L, Cevenini R.
    J Antimicrob Chemother; 1999 Jun; 43(6):825-7. PubMed ID: 10404322
    [Abstract] [Full Text] [Related]

  • 15. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
    Riska PF, Kutlin A, Ajiboye P, Cua A, Roblin PM, Hammerschlag MR.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3586-90. PubMed ID: 15328134
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM, Reznik T, Hammerschlag MR.
    Int J Antimicrob Agents; 2003 Jun; 21(6):578-80. PubMed ID: 12791473
    [Abstract] [Full Text] [Related]

  • 17. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Malay S, Roblin PM, Reznik T, Kutlin A, Hammerschlag MR.
    Antimicrob Agents Chemother; 2002 Feb; 46(2):517-8. PubMed ID: 11796366
    [Abstract] [Full Text] [Related]

  • 18. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae.
    Gnarpe J, Eriksson K, Gnarpe H.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1843-5. PubMed ID: 8843291
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activity of garenoxacin against Chlamydia spp.
    Donati M, Pollini GM, Sparacino M, Fortugno MT, Laghi E, Cevenini R.
    J Antimicrob Chemother; 2002 Sep; 50(3):407-10. PubMed ID: 12205067
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
    Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T.
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1331-4. PubMed ID: 9174194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.